Does surgical removal of primary melanoma trigger growth of occult metastases? An analytical epidemiological approach

Dermatologic Surgery

Volumn 23, Issue 11, 1997, Pages 1043-1046

  Smolle, Josef ^a   Soyer, H Peter ^a   Smolle Jüttner, Freyja Maria ^a   Rieger, Edgar ^a   Kerl, Helmut ^a  

^a UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GROWTH; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 0030840114     PISSN: 10760512     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4725.1997.tb00445.x     Document Type: Article

References (30)

1. Oliver RTD. Does surgery disseminate or accelerate cancer? Lancet 1996;346:1506-7.
2. Iversen P, Madsen PO, Corle DK. Radical prostatectomy versus expectant treatment for early carcinoma of the prostate: 23 year follow up of prospective randomised study. Scand J Urol Nephrol 1995;172:65-72.
3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine 1995;1:27-31.
4. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
5. Garbe C, Buettner P, Ellwanger U, et al. Das zentralregister malignes melanom der Deutschen dermatologischen gesellschaft in den Jahren 1983-1993. Epidemiologische entwicklungen und aktuelle therapeutische versorgung des malignen melanoms der haut. Hautarzt 1995;46:683-92.
6. Bahmer FA, Schild R. Die vertikale tumordicke als Schätzer des tatsächlichen tumor-volumens [Vertical tumor thickness as an estimator of the actual tumor volume]. Z Hautkr 1990;65:901-4.
7. Bortz J. Lehrbuch der Statistik für Sozialwissenschaftler 2nd ed. Berlin: Springer, 1985.
8. Swartzendruber DE, Retsky MW, Wardwell RH, Bame PD. An alternative approach for treatment of breast cancer. Breast Cancer Res Treat 1994;32:319-25.
9. Friedman RJ, Rigel DS, Kopf AW, Grin CM, et al. Volume of malignant melanoma is superior to thickness as a prognostic indicator. Preliminary observation. Dermatol Clin 1991;9:643-8.
10. Sondergaard K, Schou G. Survival with primary cutaneous malignant melanoma, evaluated from 2012 cases. A multivariate regression analysis. Virchows Arch A 1985;406:179-95.
11. Karakousis CP, Emrich LJ, Rao U. Tumor thickness and prognosis in clinical stage I malignant melanoma. Cancer 1989;64:1432-6.
12. Breslow A. Thickness, cross-sectional area and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970;172: 902-8.
13. Haddad FS, Haddad L, Griffin EE, Haddad R, Haddad Z. Doubling time and annual doubling rate of human prostatic cancer. Urology 1987;29:35-9.
14. Blomqvist C, Wiklund T, Tarkkanen M, Elomaa I, Virolainen M. Measurement of growth rate of lung metastases in 21 patients with bone or soft-tissue sarcoma. Br J Cancer 1993;68:414-7.
15. Rooser B, Pettersson H, Alvegard T. Growth rate of pulmonary metastases from soft tissue sarcoma [published erratum appears in Acta Oncol 1987;26:496]. Acta Oncol 1987;26:189-92.
16. Cho KG, Hoshino T, Nagashima T, Murovic JA, Wilson CB. Prediction of tumor doubling time in recurrent meningiomas. Cell kinetics studies with bromodeoxyuridine labeling. J Neurosurg 1986;65:790-4.
17. Schotteri HD, Paul E. Growth dynamics of malignant melanomas. Determination of tumor doubling time based on morphometric measurements of roentgen images of lung metastases. Z Hautkr 1988;63:481-7.
18. Takahashi Y, Mai M, Kusama S. Factors influencing growth rate of recurrent stomach cancers as determined by analysis of serum carcinoembryonic antigen. Cancer 1995;75:1497-1502.
19. Yamashita T, Kuwabara T. Estimation of rate of growth of malignant brain tumors by computed tomography scanning. Surg Neurol 1983;20:464-70.
20. Greengard O, Head JF, Goldberg SL, Kirschner PA. Biochemical measure of the volume doubling time of human pulmonary neoplasms. Cancer 1985;55:1530-5.
21. Okada S, Okazaki N, Nose H, et al. Follow-up examination schedule of postoperative HCC patients based on tumor volume doubling time. Hepatogastroenterology 1993;40:311-5.
22. Okazaki N, Yoshino M, Yoshida T, et al. Evaluation of the prognosis for small hepatocellular carcinoma based on tumor volume doubling time. A preliminary report. Cancer 1989;63:2207-10.
23. Peer PG, van Dijck JA, Hendriks JH, Holland R, Verbeek AL. Age-dependent growth rate of primary breast cancer. Cancer 1993;71:3547-51.
24. Havelaar IJ, Sugarbaker PH, Vermess M, Miller DL. Rate of growth of intraabdominal metastases from colorectal cancer. Cancer 1984;54:163-71.
25. Yu H, Diamandis EP, Prestigiacomo AF, Stamey TA. Ultrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy. Clin Chem 1995;41:430-4.
26. Finlay IG, Meek D, Brunton F, McArdle CS. Growth rate of hepatic metastases in colorectal carcinoma. Br J Surg 1988;75:641-4.
27. Augsburger JJ, Gonder JR, Amsel J, Shields JA, Donoso LA. Growth rates and doubling times of posterior uveal melanomas. Ophthalmology 1984;91:1709-15.
28. Usuda K, Saito Y, Aikawa H, Sakurada A, Chen Y, Takahashi S, Kanma K, Sato M, Sagawa M, Fujimura S. Flow cytometric analysis of nuclear DNA content of lung cancer: correlation between nuclear DNA content and tumor doubling time. Nippon Kyobu Geka Gakkai Zasshi 1994;42:486-91.
29. Ide M, Jimbo M, Yamamoto M, Umebara Y, Hagiwara S, Kubo O. Growth rate of intracranial meningioma: tumor doubling time and proliferating cell nuclear antigen staining index. Neurol Med Chir Tokyo 1995;35:289-93.
30. Laasonen EM, Troupp H. Volume growth rate of acoustic neurinomas. Neuroradiology 1986;28:203-7.